A patient with type 1 diabetes was prescribed a glucocorticoid for COPD. Which will the nurse expect in this patient?

Choice A reason: The cells of the myocardium become hypertrophic in response to increased workload or pressure, not as a result of myocardial infarction. Hypertrophy is an adaptive mechanism that can lead to impaired ventricular function over time.

Choice B reason: The resulting hypoxia leads to ischemic injury and myocardial cell death. This is the main cause of impaired ventricular function after a myocardial infarction. The loss of viable myocardial tissue reduces the contractility and pumping ability of the heart.

Choice C reason: There is a temporary alteration in electrolyte balance that can be corrected. This is not the primary cause of impaired ventricular function after a myocardial infarction. Electrolyte imbalance can occur due to fluid loss, renal impairment, or medication side effects, but it can be managed with appropriate interventions.

Choice D reason: There is too much pressure on the heart and the ventricles begin to dysfunction. This is not the direct cause of impaired ventricular function after a myocardial infarction. Increased pressure on the heart can result from hypertension, valvular disease, or pulmonary embolism, but it is not related to myocardial ischemia or necrosis.

Choice A reason: Montelukast does not increase vessel permeability. It blocks the effects of leukotrienes, which are inflammatory mediators that cause vessel permeability, bronchoconstriction, and mucus secretion. By blocking leukotrienes, montelukast reduces vessel permeability and inflammation.

Choice B reason: Montelukast reduces bronchoconstriction and mucus secretion. It blocks the effects of leukotrienes, which are inflammatory mediators that cause bronchoconstriction and mucus secretion. By blocking leukotrienes, montelukast improves airflow and reduces asthma symptoms.

Choice C reason: Montelukast does not increase inflammation. It blocks the effects of leukotrienes, which are inflammatory mediators that cause inflammation, bronchoconstriction, and mucus secretion. By blocking leukotrienes, montelukast reduces inflammation and prevents asthma exacerbations.

Choice D reason: Montelukast does not increase bronchoconstriction. It blocks the effects of leukotrienes, which are inflammatory mediators that cause bronchoconstriction, mucus secretion, and inflammation. By blocking leukotrienes, montelukast reduces bronchoconstriction and improves airflow.